Regeneron’s Eylea HD Receives FDA Complete Response Letter Despite Priority Review
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that it has received a Complete Response Letter (CRL)...
Hengrui Gains NMPA Approval for Phase III Study of SHR-8068 in PD-L1 Negative NSCLC
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has received approval from the National Medical...
Kelun-Biotech Gains FDA Clearance for Phase I Trial of ADC SKB518
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced that it has received clearance from the...
Grand Pharma’s GPN02006 Shows Promising HCC Diagnostic Results in Trial
China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) has reported excellent outcomes from the investigator-initiated...
Shanghai Operation Robot Secures RMB 100 Million Series C Funding for AI-Driven Surgical Robot Development
Shanghai-based medical robotics developer Operation Robot Co., Ltd. has reportedly raised close to RMB 100...
Novo Nordisk Partners with JD Healthcare to Advance Obesity and Diabetes Management
Denmark-based Novo Nordisk (NYSE: NVO) has entered into a collaboration with JD Healthcare, a subsidiary...
Novo Nordisk’s Wegovy Gets NMPA Label Update for Cardiovascular Risk Reduction
China’s National Medical Products Administration (NMPA) has approved a label update for Novo Nordisk’s (NYSE:...
Broncus Medical Secures NMPA Approval for BroncAblate in Lung Cancer Treatment
Broncus Medical Inc. (HKG: 2216), a provider of precision intervention solutions for lung disease, announced...
Rona Therapeutics Wins NMPA IND Approval for siRNA Hypertension Drug RN1871
Shanghai-based Rona Therapeutics Inc., a developer of siRNA medicines, has announced that it has received...
Shanghai Pharmaceuticals Partners with Organon to Market Women’s Health Products in China
China’s Shanghai Pharmaceuticals Holding Ltd (SPH, HKG: 2607, SHA: 601607) has entered into a hospital-channel...
HutchMed Completes Patient Enrollment for Orpathys in Gastric Cancer Trial
HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced the completion of patient enrollment for the...
Akeso’s Ebdarokimab Receives NMPA Approval for Moderate to Severe Plaque Psoriasis
China’s Akeso Biopharma (HKG: 9926) announced that it has received marketing approval from the National...
Shanghai Healthcare Administration Pushes for 11th Round of VBP
Shanghai’s Healthcare Security Administration (HSA) bureau held a work conference on April 16, 2025, to...
Vivolight’s Multimodal Coronary OCT System Gains FDA Clearance
Shenzhen-based minimally invasive laser medical device firm Vivolight Medical Device & Technology Co., Ltd has...
Belief BioMed Gains NMPA Clinical Trial Approval for DMD Gene Therapy BBM-D101
China-based gene therapy specialist Belief BioMed Inc. (BBM) has announced that it has received clinical...
Sanofi’s Dupixent Approved by FDA for Chronic Spontaneous Urticaria
France-based pharmaceutical major Sanofi (EPA: SAN, NASDAQ: SNY) has announced that the US Food and Drug...
Biogen’s High-Dose Spinraza Regimen Accepted for CDE Review in China
US-based Biogen Inc. (NASDAQ: BIIB) announced that the Center for Drug Evaluation (CDE) in China...
Sichuan Biokin Gains NMPA Approval for Phase II Trials of BL-B01D1 in Combination Therapies
China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has received approval from the National Medical...
Walvax Biotech Gains NMPA Clinical Clearance for 20-Valent Pneumococcal Vaccine
China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced receiving clinical trial clearance from the...
Asieris Pharmaceuticals Reports Strong 2024 Financial Results for Urogenital Cancer Drugs
hina-based urogenital cancer specialist Asieris Pharmaceuticals (SHA: 688176) has released its 2024 financial report. In...